RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2011 /PRNewswire/ -- Talecris Biotherapeutics Holdings Corp. ("Talecris") (Nasdaq: TLCR) today announced its financial results for the three and twelve months ended December 31, 2010 and filed its Form 10-K with the U.S. Securities and Exchange Commission (SEC).
Fourth quarter 2010 net revenue increased by $20.7 million or 5.3% to $410.8 million from $390.1 million in the fourth quarter of 2009. Higher revenues from Talecris' principal products Gamunex-C®/Gamunex® Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV) and Prolastin® Alpha-1 Proteinase Inhibitor (Human) (Prolastin, Prolastin A1PI, Prolastin-C A1PI) as well as Thrombate® III Antithrombin III (Human) in the fourth quarter of 2010 were partially offset by lower sales of albumin, hyperimmunes and contract manufacturing compared to the fourth quarter of 2009. Fourth quarter 2010 gross margin was 41.2% compared to 39.2% in the fourth quarter of 2009. Fourth quarter 2010 income from operations was $68.5 million versus $57.4 million for the fourth quarter of 2009, a 19.3% increase. Net income was $17.1 million for the fourth quarter of 2010, an increase of $15.7 million compared to net income of $1.4 million for the fourth quarter of 2009. Diluted earnings per share were $0.13 in the fourth quarter of 2010, including an after-tax charge of $6.3 million ($0.05 per diluted share) for costs associated with Talecris' definitive merger agreement with Grifols S.A. and Grifols, Inc. (Grifols) as well as an after-tax charge of $26.6 million ($0.20 per diluted share) as the result of the Plasma Centers of America, LLC (PCA) jury verdict and related interest expense, compared to diluted earnings per share of $0.01 (pro forma diluted EPS of $0.00) for the fourth quarter of 2009. Talecris' fourth quarter 2009
|SOURCE Talecris Biotherapeutics Holdings Corp.|
Copyright©2010 PR Newswire.
All rights reserved